Source: Pharmacy Times articles
Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.
Recent Content
- Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
- Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
- Refining renal response assessment in monoclonal immunoglobulin deposition disease: Challenges, limitations and need for consensus
- Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma
- Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
- Video: Pharmacists Take Center Stage in Delivering Linvoseltamab, Advancing Myeloma Care
- SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma
- FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma
- Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT
- Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement